Varnitha Manikantan

Precision gene editing in infant neuroblastoma: a review of nanoparticle: enabled CRISPR/Cas9 therapies

Infant neuroblastoma (NB), defined by diagnosis during the first year of life, represents a clinically heterogeneous disease spectrum ranging from localized tumours with favourable outcomes and a capacity for spontaneous regression, to high-risk metastatic disease requiring inten...

A review on intranasal nanoparticle delivery systems for blood–brain barrier penetration in medulloblastoma therapeutics: current insights and future perspectives

Accounting for approximately 20% of all childhood central nervous system (CNS) malignancies, medulloblastoma is the most common malignant pediatric brain tumor. Current standard-of-care treatment, comprising craniospinal irradiation, adjuvant chemotherapy, and surgical resection...